TruScreen Group Limited — Board/Management Information 2021

Feb 25, 2021

NZX Announcement

26 February 2021

==> picture [155 x 169] intentionally omitted <==

TRUSCREEN EXECUTIVE LEADERSHIP CHANGE

• Termination of Ms. Victoria Potarina as Chief Executive Officer

• Appointment of current director Ms. Juliet Hull as Interim Chief Executive Officer

TruScreen Group Limited (the Company) advises that, the Executive Service Agreement with Ms. Victoria Potarina, Chief Executive Officer of the Company, was terminated with immediate effect.

Ms. Juliet Hull, a Non-Executive Director of the Company will assume an executive role as Interim Chief Executive Officer. Juliet holds a MBA from Macquarie Graduate School of Management and was previously the General Manager and Country Director of Johnson & Johnson New Zealand. Her extensive leadership experience included working within the healthcare sectors in Australia and New Zealand with distributors and public health systems across Greater Asia and Pacific.

“On behalf of the Board, I thank Victoria for her contribution to the company. Over the past year TruScreen has strengthened its technology and service delivery team. With our existing teams, and under the guidance of Juliet, we remain well-positioned to continue our focus on growing sales in our core market of China and continue to supplement this with our expansion into the developing markets of Mexico, Vietnam, Middle East, Russia, and Central Eastern Europe,” said Tony Ho, Chairman of Truscreen.

The Company will commence a recruitment process for a new Chief Executive to lead the Company through its next phase of development.

This release to NZX/ASX has been authorised by the Board.

For more information visit www.TruScreen.com or contact:

TruScreen	TruScreen	Investor Relations
Tony Ho	Juliet Hull	Trevor Chappell
Chairman	CEO
tonyho@truscreen.com	juliethull@truscreen.com	Tchappel@we-worldwide.com

-ENDS-

==> picture [155 x 169] intentionally omitted <==

About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing realtime, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is significant.